18 • Probe •Vol LXII • No. 3 • May–Aug 2023 Clinical Evidence 2 Efficacy of Liv.52® in the Management of Infective Hepatitis Aim To evaluate the efficacy of Liv.52 in the treatment of infective hepatitis Materials and Methods This controlled study included 50 patients (aged 15–65 y) with infective hepatitis, admitted to Darbhanga Medical College Hospital (Darbhanga, Bihar, India). The patients were equally divided into 2 groups: the treatment group received Liv.52 (6 tablets in divided doses) along with vitamin B complex and corticosteroids, daily, and the control group received vitamin B complex and corticosteroids only. All the patients underwent clinical examination, laboratory tests for total and differential white blood cell count, and stool and urine analyses. To assess the derangement in the liver function, specific tests such as estimations of serum bilirubin, alkaline phosphatase (ALP), thymol turbidity, serum glutamic pyruvic transaminase (SGPT), and serum glutamic oxaloacetic transaminase (SGOT) were carried out initially. These tests were repeated after 4 and 8 weeks of treatment to assess the degree of improvement in both the groups. Results The symptoms of infective hepatitis subsided substantially faster in the Liv.52 group than that in the control group—about half to two-thirds of the time taken in the control group (Figure 1). Liver function tests Serum bilirubin: The serum bilirubin level ranged from 5 to 22 mg% (average 12.8 mg%) in the Liv.52 group, and 5 to 18 mg% (average 12.06 mg%) in the control group. The serum bilirubin level decreased to 4.81 and 1.8 mg% in the control and Liv.52 groups, Figure 1. A Comparison of the Effect of the Respective Treatments on the Symptoms of Infective Hepatitis Figure 2. Effect of Liv.52 on Liver Function Parameters respectively, after 8 weeks of treatment (Table). In the Liv.52 group, the percentage reduction was 61% after 4 weeks and 86% after 8 weeks of treatment (Figure 2). Serum ALP: In the Liv.52 group, the serum ALP values were 14.72 and 11.08 KA units after 4 and 8 weeks of the treatment, respectively, which indicate reduction of 23% and 42%, respectively, compared with the initial values. Thymol turbidity: In the Liv.52 group, the average values were 6.8 and 3.64 units after 4 and 8 weeks, respectively, whereas in the control group, the values were 8.4 and 6 units, respectively (Figure 2). After 4 B: Before Treatment A: After Treatment Liv.52 Control (B) 25 (B) 25 (B) 22 (B) 22 (B) 23 (B) 23 (B) 25 (A) 12 (A) 15 (A) 6 (A) 10 (A) 10 25 25 (A) 4 (A) 9 (A) 6 (B) 20 Jaundice Loss of Appetite Loss of Weight Epigastric Discomfort Total No. of Cases 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 Initial Initial Initial 4 wk 4 wk 4 wk 8 wk 8 wk 8 wk Serum Alkaline Phosphatase Values Thymol Turbidity Values Liv.52 Control
RkJQdWJsaXNoZXIy MjAwNDg=